In The News
Insurer Marsh breached obligation in case over $7B Greensill collapse: court
Novartis loses case against Pharmacor over blood pressure drug
MinRes admits it should have disclosed related-party transactions
High Court says church not vicariously liable for historic abuse
Social media companies to face new duty of care regulations
Competing Harvey Norman class actions get one more month to nut out deal
ANZ, OnePath class action members to pocket 65% of settlement if costs OK’d
HFW bolsters insurance team with recruits from Dentons, Meridian
Consumer watchdog to target ‘NDIS approved’ advertising claims
WiseTech Global faces class action by shareholders
Please login to bookmarkClose

Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au